• ACADIA Pharmaceuticals said the FDA granted Fast Track designation to remlifanserin for hallucinations and delusions in Alzheimer’s disease psychosis.
• RADIANT Phase 2 enrollment is complete; topline results expected in September to October 2026.
• Screening and enrollment are underway in the Phase 3 studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720458854) on July 20, 2026, and is solely responsible for the information contained therein.